Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:age |
9 to 45 years
|
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
J07BM01
|
| gptkbp:broadcastOn |
2 or 3 dose series
|
| gptkbp:contains |
gptkb:L-histidine
gptkb:polysorbate_80 sodium chloride boric acid HPV type 11 L1 protein HPV type 16 L1 protein HPV type 18 L1 protein HPV type 6 L1 protein amorphous aluminum hydroxyphosphate sulfate |
| gptkbp:contraindication |
severe allergic reaction to previous dose
hypersensitivity to any component |
| gptkbp:countryOfOperation |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States many other countries |
| https://www.w3.org/2000/01/rdf-schema#label |
Gardasil
|
| gptkbp:indication |
prevention of anal cancer
prevention of cervical cancer prevention of genital warts prevention of precancerous or dysplastic lesions prevention of vaginal cancer prevention of vulvar cancer |
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketedAs |
Silgard (in some countries)
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:relatedTo |
gptkb:Cervarix
gptkb:Gardasil_9 |
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
nausea dizziness headache swelling at injection site pain at injection site redness at injection site |
| gptkbp:usedFor |
prevention of human papillomavirus (HPV) infection
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Merck_&_Co.
|
| gptkbp:bfsLayer |
4
|